CO5560576A2 - Inhibidores de proteasa de cisteina con estructura de 2- ciano 4-amino-pirimidina y actividad inhibidora de captesina k para el tratamiento de inflamaciones y otras enfermedades - Google Patents
Inhibidores de proteasa de cisteina con estructura de 2- ciano 4-amino-pirimidina y actividad inhibidora de captesina k para el tratamiento de inflamaciones y otras enfermedadesInfo
- Publication number
- CO5560576A2 CO5560576A2 CO04016657A CO04016657A CO5560576A2 CO 5560576 A2 CO5560576 A2 CO 5560576A2 CO 04016657 A CO04016657 A CO 04016657A CO 04016657 A CO04016657 A CO 04016657A CO 5560576 A2 CO5560576 A2 CO 5560576A2
- Authority
- CO
- Colombia
- Prior art keywords
- lower alkyl
- heterocyclyl
- cycloalkyl
- aryl
- molecule
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- -1 R6 is H Chemical group 0.000 abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000005330 8 membered heterocyclic group Chemical group 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000005257 alkyl acyl group Chemical group 0.000 abstract 1
- 125000003368 amide group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000005251 aryl acyl group Chemical group 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 150000002829 nitrogen Chemical class 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
1.- Un compuesto de la fórmula 1, o una sal o éster farmacéuticamente aceptable del mismo caracterizado porque en donde R es H, -R4, -OR4 o NR3R4, en donde R3 es H, alquilo inferior o cicloalquilo con molécula de 3 a 10 átomos de carbono, y R4 es alquilo inferior o cicloalquilo con molécula de 3 a 10 átomos de carbono, y en donde R3 y R4 se substituyen independientemente, opcionalmente por halo, hidroxi, alcoxi inferior, CN, NO2, u opcionalmente amino substituidos con mono- o di-alquilo inferior;R1 es -CO-NR5R6, -NH-CO-R5, -CH2-NH-C(O)-R5, -CO-R5, -S(O)R5, -S(O)2-R5, -CH2-CO-R5 o -CH2-NR5R6, en donde R5 es arilo, arilo-alquilo inferior, cicloalquilo con molécula de 3 a 10 átomos de carbono, cicloalquilo con molécula de 3 a 10 átomos de carbono-alquilo inferior, heterociclilo o heterociclilo-alquilo-alquilo inferior, R6 es H, arilo, arilo-alquilo inferior, arilo-alquenilo inferior, cicloalquilo con molécula de 3 a 10 átomos de carbono, cicloalquilo con molécula de 3 a 10 átomos de carbono-alquilo inferior, heterociclilo o heterociclilo-alquilo inferior, oen donde R5 y R6 junto con el átomo de nitrógeno al cual se unen forman un grupo N-heterociclilo,en donde N-heterociclilo denota un nitrógeno saturado, parcialmente no saturado o aromático que contiene una mitad heterocíclica unida a través de un átomo de nitrógeno de la misma que tiene de 3 a 8 átomos anulares que contienen opcionalmente 1, 2, o 3 átomos heterogéneos adicionales seleccionados de entre N, NR7, O, S, S(O) o S(O)2 en donde R7 es H u opcionalmente substituido (alquilo inferior, carboxi, acilo (incluyendo tanto el acilo de alquilo inferior, por ejemplo, formilo, acetilo o propionilo, o acilo de arilo, por ejemplo, benzoílo), amido, arilo, S(O) o S(O)2), y en donde el N-heterociclilo se fusiona opcionalmente en una estructura bicíclica, por ejemplo, con un anillo de benceno o piridina, y en donde el N-heterociclilo se enlaza opcionalmente en una estructura espiral con un anillo heterocíclico o de cicloalquilo integrado de 3 a 8 miembros en el que el anillo heterocíclico tiene de 3 a 10 miembros anulares y contiene de 1 a 3 átomos heterogéneos seleccionados de entre N,...
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0121026.9A GB0121026D0 (en) | 2001-08-30 | 2001-08-30 | Organic compounds |
| GB0121024A GB0121024D0 (en) | 2001-08-30 | 2001-08-30 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5560576A2 true CO5560576A2 (es) | 2005-09-30 |
Family
ID=26246490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04016657A CO5560576A2 (es) | 2001-08-30 | 2004-02-25 | Inhibidores de proteasa de cisteina con estructura de 2- ciano 4-amino-pirimidina y actividad inhibidora de captesina k para el tratamiento de inflamaciones y otras enfermedades |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7112589B2 (es) |
| EP (1) | EP1423121B1 (es) |
| JP (1) | JP4131701B2 (es) |
| KR (1) | KR100629834B1 (es) |
| CN (1) | CN1549717B (es) |
| AR (1) | AR036375A1 (es) |
| AT (1) | ATE345136T1 (es) |
| AU (1) | AU2002333758B2 (es) |
| BR (1) | BR0212141A (es) |
| CA (1) | CA2456127C (es) |
| CO (1) | CO5560576A2 (es) |
| DE (1) | DE60216122T2 (es) |
| ES (1) | ES2275946T3 (es) |
| HU (1) | HUP0401431A3 (es) |
| IL (1) | IL160295A0 (es) |
| MX (1) | MXPA04001930A (es) |
| NZ (1) | NZ531287A (es) |
| PE (1) | PE20030772A1 (es) |
| PL (1) | PL208280B1 (es) |
| PT (1) | PT1423121E (es) |
| RU (1) | RU2326119C2 (es) |
| WO (1) | WO2003020278A1 (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR036375A1 (es) * | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| SE0201976D0 (sv) * | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| GB0220187D0 (en) * | 2002-08-30 | 2002-10-09 | Novartis Ag | Organic compounds |
| TW200510436A (en) * | 2003-07-21 | 2005-03-16 | Novartis Ag | Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss |
| WO2005011703A1 (en) * | 2003-08-04 | 2005-02-10 | Akzo Nobel N.V. | 2-cyano-1,3,5-triazine-4,6-diamine derivatives |
| JP2007506741A (ja) * | 2003-09-23 | 2007-03-22 | メルク エンド カムパニー インコーポレーテッド | 向代謝性グルタミン酸受容体のピラゾール系調節剤 |
| MXPA06005635A (es) * | 2003-11-19 | 2006-08-17 | Novartis Ag | Uso de inhibidores de catepsina k para tratamiento de enfermedades de perdida osea severa. |
| WO2005103012A1 (ja) * | 2004-04-21 | 2005-11-03 | Ono Pharmaceutical Co., Ltd. | ヒドラジノ複素環ニトリル化合物およびその用途 |
| TW200614993A (en) | 2004-06-11 | 2006-05-16 | Akzo Nobel Nv | 4-phenyl-pyrimidine-2-carbonitrile derivatives |
| AR050858A1 (es) * | 2004-09-07 | 2006-11-29 | Glaxo Group Ltd | Compuesto de heteroaril-nitrilo sustituido, su uso para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para la preparacion del mismo |
| WO2006040300A1 (en) * | 2004-10-12 | 2006-04-20 | N.V. Organon | 4-cycloalkyl-pyrimidine-2-carbonitrile derivatives |
| IL164942A0 (en) * | 2004-10-31 | 2005-12-18 | Yeda Res & Dev | The use of a protease or a protease inhibitor for the manufacture of medicaments |
| GB0514684D0 (en) * | 2005-07-18 | 2005-08-24 | Novartis Ag | Organic compounds |
| AU2006277678B2 (en) * | 2005-08-05 | 2012-04-19 | Hybrigenics Sa | Novel cysteine protease inhibitors and their therapeutic applications |
| TW200804352A (en) * | 2005-09-02 | 2008-01-16 | Glaxo Group Ltd | Novel cysteine protease inhibitors |
| US7326715B2 (en) | 2005-09-23 | 2008-02-05 | N.V. Organon | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives |
| TW200745055A (en) * | 2005-09-23 | 2007-12-16 | Organon Nv | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives |
| US7687515B2 (en) | 2006-01-17 | 2010-03-30 | N.V. Organon | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
| AU2007253796A1 (en) * | 2006-05-22 | 2007-11-29 | Velcura Therapeutics, Inc. | Use of Cathepsin K antagonists in bone production |
| CN101479269A (zh) * | 2006-06-23 | 2009-07-08 | 阿斯利康(瑞典)有限公司 | 蝶啶衍生物及其作为组织蛋白酶抑制剂的用途 |
| EP1947091A1 (en) * | 2007-01-16 | 2008-07-23 | Glaxo Group Limited | Pyrimidyl nitrile derivatives as cysteine protease inhibitors |
| US7932251B2 (en) | 2007-07-16 | 2011-04-26 | N.V. Organon | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
| KR101595238B1 (ko) | 2007-12-21 | 2016-02-18 | 리간드 파마슈티칼스 인코포레이티드 | 선택적 안드로겐 수용체 조절제(ｓａｒｍ) 및 이의 용도 |
| EP2719700A1 (en) | 2008-01-09 | 2014-04-16 | Amura Therapeutics Limited | Tetrahydrofuro(3,2-b)pyrrol-3-one derivatives as inhibitors of cysteine proteinases |
| TW201035094A (en) | 2009-01-16 | 2010-10-01 | Organon Nv | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
| US8026236B2 (en) | 2009-01-16 | 2011-09-27 | N.V. Organon | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
| EP2316820A1 (en) * | 2009-10-28 | 2011-05-04 | Dompe S.p.A. | 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them |
| US9115126B2 (en) | 2010-01-15 | 2015-08-25 | Merck Sharp & Dohme B.V. | 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives |
| AU2011311452B2 (en) | 2010-10-06 | 2016-09-01 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the diagnosis, prognosis and treatment of breast cancer metastasis |
| US8524710B2 (en) * | 2010-11-05 | 2013-09-03 | Hoffmann-La Roche Inc. | Pyrrolidine derivatives |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| CA2875918A1 (en) | 2012-06-06 | 2013-12-12 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
| HK1213946A1 (zh) | 2012-10-12 | 2016-07-15 | Inbiomotion S.L. | 用於使用c-maf对前列腺癌转移进行诊断、预後和治疗的方法 |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| WO2014184679A2 (en) | 2013-03-15 | 2014-11-20 | Inbiomotion S.L. | Method for the prognosis and treatment of renal cell carcinoma metastasis |
| AU2014229505B2 (en) | 2013-03-15 | 2020-02-27 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| ES2727904T3 (es) | 2013-10-09 | 2019-10-21 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Método para el pronóstico y tratamiento de cáncer metastatizante del hueso que se origina a partir de cáncer de mama |
| US10441567B2 (en) | 2014-01-17 | 2019-10-15 | Ligand Pharmaceuticals Incorporated | Methods and compositions for modulating hormone levels |
| CA2967224C (en) | 2014-12-11 | 2023-08-22 | Inbiomotion S.L. | Binding members for human c-maf |
| WO2017203468A1 (en) | 2016-05-25 | 2017-11-30 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf status |
| BR112019015399A2 (pt) * | 2017-01-27 | 2020-03-31 | Genfit | Moduladores de rorgama e usos dos mesmos |
| CN108586356B (zh) * | 2017-03-16 | 2021-02-19 | 杭州科巢生物科技有限公司 | 瑞博西尼新中间体及其制备瑞博西尼的合成方法 |
| AU2018372762B2 (en) | 2017-11-22 | 2025-08-21 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf status |
| CN109467536B (zh) * | 2018-12-23 | 2020-06-05 | 沧州普瑞东方科技有限公司 | 2-氯/羟基嘧啶-5-羧酸的合成方法 |
| EP3946332A1 (en) | 2019-04-05 | 2022-02-09 | Université de Bretagne Occidentale | Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning |
| CA3133929A1 (en) | 2019-04-19 | 2020-10-22 | Lin Zhi | Crystalline forms and methods of producing crystalline forms of a compound |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1251074B (de) | 1960-11-02 | 1967-09-28 | J R Geigy A -G , Basel (Schweiz) | Selektives Herbizid |
| NL295648A (es) * | 1962-07-26 | |||
| BR6915234D0 (pt) | 1969-05-22 | 1973-06-07 | American Cyanamid Co | Novos derivados de melamina e processo para sua preparaca |
| CH627919A5 (de) | 1977-04-14 | 1982-02-15 | Ciba Geigy Ag | Herbizide mittel. |
| EP0850228A1 (en) * | 1995-09-01 | 1998-07-01 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
| EP0880501A1 (en) | 1996-02-02 | 1998-12-02 | Zeneca Limited | Heterocyclic compounds useful as pharmaceutical agents |
| DE19817459A1 (de) * | 1998-04-20 | 1999-10-21 | Basf Ag | Neue heterozyklische substituierte Amide, Herstellung und Anwendung |
| RU2255937C2 (ru) * | 1999-09-13 | 2005-07-10 | Берингер Ингельхайм Фармасьютиклз, Инк. | Новые производные гетероциклических соединений, фармацевтическая композиция, способ модуляции аутоиммунных заболеваний, способ получения этих соединений |
| CN102584799A (zh) | 1999-09-16 | 2012-07-18 | 田边三菱制药株式会社 | 含氮的6-员芳香环化合物 |
| CN1657523A (zh) | 2000-04-28 | 2005-08-24 | 田边制药株式会社 | 环状化合物 |
| GB0013383D0 (en) | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| AR036375A1 (es) * | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| SE0201976D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
-
2002
- 2002-08-28 AR ARP020103230A patent/AR036375A1/es not_active Application Discontinuation
- 2002-08-29 HU HU0401431A patent/HUP0401431A3/hu unknown
- 2002-08-29 AU AU2002333758A patent/AU2002333758B2/en not_active Ceased
- 2002-08-29 MX MXPA04001930A patent/MXPA04001930A/es active IP Right Grant
- 2002-08-29 RU RU2004109812/04A patent/RU2326119C2/ru not_active IP Right Cessation
- 2002-08-29 ES ES02797650T patent/ES2275946T3/es not_active Expired - Lifetime
- 2002-08-29 PL PL367821A patent/PL208280B1/pl not_active IP Right Cessation
- 2002-08-29 US US10/487,741 patent/US7112589B2/en not_active Expired - Fee Related
- 2002-08-29 DE DE60216122T patent/DE60216122T2/de not_active Expired - Lifetime
- 2002-08-29 NZ NZ531287A patent/NZ531287A/en unknown
- 2002-08-29 WO PCT/EP2002/009661 patent/WO2003020278A1/en not_active Ceased
- 2002-08-29 BR BR0212141-7A patent/BR0212141A/pt not_active IP Right Cessation
- 2002-08-29 PT PT02797650T patent/PT1423121E/pt unknown
- 2002-08-29 AT AT02797650T patent/ATE345136T1/de active
- 2002-08-29 IL IL16029502A patent/IL160295A0/xx unknown
- 2002-08-29 PE PE2002000834A patent/PE20030772A1/es not_active Application Discontinuation
- 2002-08-29 EP EP02797650A patent/EP1423121B1/en not_active Expired - Lifetime
- 2002-08-29 CA CA002456127A patent/CA2456127C/en not_active Expired - Fee Related
- 2002-08-29 CN CN028169638A patent/CN1549717B/zh not_active Expired - Fee Related
- 2002-08-29 KR KR1020047002973A patent/KR100629834B1/ko not_active Expired - Fee Related
- 2002-08-29 JP JP2003524585A patent/JP4131701B2/ja not_active Expired - Fee Related
-
2004
- 2004-02-25 CO CO04016657A patent/CO5560576A2/es not_active Application Discontinuation
-
2005
- 2005-11-30 US US11/291,007 patent/US20060074092A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1423121B1 (en) | 2006-11-15 |
| CA2456127A1 (en) | 2003-03-13 |
| US7112589B2 (en) | 2006-09-26 |
| PE20030772A1 (es) | 2003-10-02 |
| ATE345136T1 (de) | 2006-12-15 |
| RU2004109812A (ru) | 2005-10-20 |
| HUP0401431A3 (en) | 2004-11-29 |
| DE60216122T2 (de) | 2007-09-06 |
| PL367821A1 (en) | 2005-03-07 |
| BR0212141A (pt) | 2004-08-24 |
| AU2002333758B2 (en) | 2006-01-19 |
| WO2003020278A1 (en) | 2003-03-13 |
| CA2456127C (en) | 2009-10-20 |
| NZ531287A (en) | 2005-12-23 |
| JP2005505550A (ja) | 2005-02-24 |
| CN1549717B (zh) | 2011-08-17 |
| CN1549717A (zh) | 2004-11-24 |
| AR036375A1 (es) | 2004-09-01 |
| JP4131701B2 (ja) | 2008-08-13 |
| US20040249153A1 (en) | 2004-12-09 |
| IL160295A0 (en) | 2004-07-25 |
| PL208280B1 (pl) | 2011-04-29 |
| PT1423121E (pt) | 2007-02-28 |
| DE60216122D1 (de) | 2006-12-28 |
| HUP0401431A2 (hu) | 2004-10-28 |
| ES2275946T3 (es) | 2007-06-16 |
| MXPA04001930A (es) | 2004-06-15 |
| RU2326119C2 (ru) | 2008-06-10 |
| KR100629834B1 (ko) | 2006-09-29 |
| KR20040029101A (ko) | 2004-04-03 |
| EP1423121A1 (en) | 2004-06-02 |
| US20060074092A1 (en) | 2006-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5560576A2 (es) | Inhibidores de proteasa de cisteina con estructura de 2- ciano 4-amino-pirimidina y actividad inhibidora de captesina k para el tratamiento de inflamaciones y otras enfermedades | |
| JP2005505550A5 (es) | ||
| PA8431301A1 (es) | Inhibidores de metaloproteinasas, composiciones farmaceuticas que los contienen y sus usos farmaceuticos y los metodos e intermedios utiles para su preparacion | |
| AR036374A1 (es) | Pirrolo pirimidinas. | |
| BR0211910A (pt) | Derivados de tiazolila 2,4,5-trissubstituìdos e a atividade antiinflamatória dos mesmos | |
| EP1070710A3 (en) | Dithiolan derivatives, their preparation and their therapeutic effect | |
| ES2077948T3 (es) | Preparacion para el cuidado externo de la piel. | |
| EA199800074A1 (ru) | Бициклические аминопроизводные и содержащие их антагонисты pgd | |
| UY25225A1 (es) | Derivados de pleuromutilina utiles como agentes antimicrobianos | |
| AR040773A1 (es) | Pirazoles utiles como inhibidores de gsk-3 | |
| FR2754260B1 (fr) | Nouveaux derives substitues de biphenyle ou de phenylpyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| KR960007545A (ko) | 합성 흥분성 아미노산 | |
| AR246963A1 (es) | Un procedimiento para la preparacion de nuevos derivados de triazol. | |
| NO20044038L (no) | Glutaminylbaserte DRIV-inhibitorer | |
| EA200800924A1 (ru) | Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортера | |
| NO2012015I1 (no) | Dapoxetine i en hver form beskyttet av basis patent nr 330562 | |
| AR035732A1 (es) | Derivados cromen-2-carboxilicos terapeuticos, uso de estos derivados para la preparacion de medicamentos, composicion farmaceutica, compuestos relacionados, y procesos para preparar estos compuestos relacionados | |
| ES2133324T3 (es) | Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso. | |
| KR940005568A (ko) | 1-아미노아세트아미도피롤, 1-아미노 아세트아미도-2-(치환된)피롤 및 관련 화합물 | |
| AR035230A1 (es) | Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos | |
| AR018706A1 (es) | Uso de una composicion farmaceutica para tratamiento de infecciones virales | |
| DK0659193T3 (da) | Blodpladeaggregationsinhibitorer | |
| AR030197A1 (es) | Compuesto n-sustituido que contiene una cadena lateral heterociclica, composicion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de un medicamento | |
| BR0008321A (pt) | Secretagogos de hormÈnio de crescimento | |
| AR042284A1 (es) | Derivados de piperidina, preparacion y composiciones farmaceuticas que las contienen; y uso de los mismos para la fabricacion de medicamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |